Celastrol attenuates human parvovirus B19 NS1‑induced NLRP3 inflammasome activation in macrophages

Huang,Chang-Lun; Chen,Der-Yuan; Tzang,Chih-Chen; Lin,Jhen-Wei; Tzang,Bor-Show; Hsu,Tsai-Ching

doi:10.3892/mmr.2023.13080

Celastrol attenuates human parvovirus B19 NS1‑induced NLRP3 inflammasome activation in macrophages

Authors:
- Chang-Lun Huang
- Der-Yuan Chen
- Chih-Chen Tzang
- Jhen-Wei Lin
- Bor-Show Tzang
- Tsai-Ching Hsu
View Affiliations

Affiliations: Division of Thoracic Surgery, Department of Surgery, Changhua Christian Medical Foundation Changhua Christian Hospital, Changhua 500, Taiwan, R.O.C., Institute of Medicine, Chung Shan Medical University, Taichung 402, Taiwan, R.O.C., School of Medicine, College of Medicine, National Taiwan University, Taipei 100, Taiwan, R.O.C.
Published online on: August 31, 2023 https://doi.org/10.3892/mmr.2023.13080
Article Number: 193
Copyright: © Huang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Human parvovirus B19 (B19V) has been strongly associated with a variety of inflammatory disorders, such as rheumatoid arthritis (RA), inflammatory bowel disease and systemic lupus erythematosus. Non‑structural protein 1 (NS1) of B19V has been demonstrated to play essential roles in the pathological processes of B19V infection due to its regulatory properties on inflammatory cytokines. Celastrol, a quinone methide isolated from Tripterygium wilfordii, has displayed substantial potential in treating inflammatory diseases, such as psoriasis and RA. However, little is known about the effects of celastrol on B19V NS1‑induced inflammation. Therefore, cell viability assay, migration assay, phagocytosis analysis, zymography assay, ELISA and immunoblotting were conducted to verify the influences of celastrol on macrophages. The present study reported the attenuating effects of celastrol on B19V NS1‑induced inflammatory responses in macrophages derived from human acute monocytic leukemia cell lines, U937 and THP‑1. Although the migration was not significantly decreased by celastrol in both U937 and THP‑1 macrophages, significantly decreased viability, migration and phagocytosis were detected in both B19V NS1‑activated U937 and THP‑1 macrophages in the presence of celastrol. Additionally, celastrol significantly decreased MMP‑9 activity and the levels of inflammatory cytokines, including IL‑6, TNF‑α and IL‑1β, in B19V NS1‑activated U937 and THP‑1 cells. Notably, significantly decreased levels of NLR family pyrin domain‑containing 3, apoptosis‑associated speck‑like, caspase‑1 and IL‑18 proteins were observed in both B19V NS1‑activated U937 and THP‑1 cells in the presence of celastrol, indicating the involvement of the inflammasome pathway. To the best of our knowledge, the present study is the first to report on the attenuating effects of celastrol on B19V NS1‑induced inflammatory responses in macrophages, suggesting a therapeutic role for celastrol in B19V NS1‑related inflammatory diseases.

View Figures

View References

1	Cossart Y: Parvovirus B19 finds a disease. Lancet. 2:988–989. 1981. View Article : Google Scholar : PubMed/NCBI
2	Qiu J, Söderlund-Venermo M and Young NS: Human parvoviruses. Clin Microbiol Rev. 30:43–113. 2017. View Article : Google Scholar : PubMed/NCBI
3	Cohen BJ and Buckley MM: The prevalence of antibody to human parvovirus B19 in England and Wales. J Med Microbiol. 25:151–153. 1988. View Article : Google Scholar : PubMed/NCBI
4	Tsujimura M, Matsushita K, Shiraki H, Sato H, Okochi K and Maeda Y: Human parvovirus B19 infection in blood donors. Vox Sang. 69:206–212. 1995. View Article : Google Scholar : PubMed/NCBI
5	Brown KE and Young NS: Parvovirus B19 in human disease. Annu Rev Med. 48:59–67. 1997. View Article : Google Scholar : PubMed/NCBI
6	Heegaard ED and Brown KE: Human parvovirus B19. Clin Microbiol Rev. 15:485–505. 2002. View Article : Google Scholar : PubMed/NCBI
7	Lehmann HW, von Landenberg P and Modrow S: Parvovirus B19 infection and autoimmune disease. Autoimmun Rev. 2:218–223. 2003. View Article : Google Scholar : PubMed/NCBI
8	Young NS and Brown KE: Parvovirus B19. N Engl J Med. 350:586–597. 2004. View Article : Google Scholar : PubMed/NCBI
9	Page C, François C, Goëb V and Duverlie G: Human parvovirus B19 and autoimmune diseases. Review of the literature and pathophysiological hypotheses. J Clin Virol. 72:69–74. 2015. View Article : Google Scholar : PubMed/NCBI
10	Ros C, Bieri J and Leisi R: The VP1u of human parvovirus B19: A multifunctional capsid protein with biotechnological applications. Viruses. 12:14632020. View Article : Google Scholar : PubMed/NCBI
11	Cotmore SF, McKie VC, Anderson LJ, Astell CR and Tattersall P: Identification of the major structural and nonstructural proteins encoded by human parvovirus B19 and mapping of their genes by procaryotic expression of isolated genomic fragments. J Virol. 60:548–557. 1986. View Article : Google Scholar : PubMed/NCBI
12	Ozawa K and Young N: Characterization of capsid and noncapsid proteins of B19 parvovirus propagated in human erythroid bone marrow cell cultures. J Virol. 61:2627–2630. 1987. View Article : Google Scholar : PubMed/NCBI
13	Kawase M, Momoeda M, Young NS and Kajigaya S: Most of the VP1 unique region of B19 parvovirus is on the capsid surface. Virology. 211:359–366. 1995. View Article : Google Scholar : PubMed/NCBI
14	Tzang BS, Tsay GJ, Lee YJ, Li C, Sun YS and Hsu TC: The association of VP1 unique region protein in acute parvovirus B19 infection and anti-phospholipid antibody production. Clin Chim Acta. 378:59–65. 2007. View Article : Google Scholar : PubMed/NCBI
15	Astell CR, Luo W, Brunstein J and St Amand J: B19 parvovirus: biochemical and molecular features. Human parvovirus B19. Anderson LJ and Young NS: Karger Publishers; Basel, Switzerland: pp. 16–41. 1997, View Article : Google Scholar
16	Gareus R, Gigler A, Hemauer A, Leruez-Ville M, Morinet F, Wolf H and Modrow S: Characterization of cis-acting and NS1 protein responsive elements in the P6 promoter of parvovirus B19. J Virol. 72:609–616. 1998. View Article : Google Scholar : PubMed/NCBI
17	Mitchell LA: Parvovirus B19 nonstructural (NS1) protein as a transactivator of interleukin-6 synthesis: Common pathway in inflammatory sequelae of human parvovirus infections? J Med Virol. 67:267–274. 2002. View Article : Google Scholar : PubMed/NCBI
18	Jalali S, Farhadi A, Rafiei Dehbidi G, Farjadian S, Sharifzadeh S, Ranjbaran R, Seyyedi N, Namdari S and Behzad-Behbahani A: The pathogenic aspects of human parvovirus B19 NS1 protein in chronic and inflammatory diseases. Interdiscip Perspect Infect Dis. 2022:16399902022. View Article : Google Scholar : PubMed/NCBI
19	Moffatt S, Tanaka N, Tada K, Nose M, Nakamura M, Muraoka O, Hirano T and Sugamura K: A cytotoxic nonstructural protein, NS1, of human parvovirus B19 induces activation of interleukin-6 gene expression. J Virol. 70:8485–8491. 1996. View Article : Google Scholar : PubMed/NCBI
20	Moffatt S, Yaegashi N, Tada K, Tanaka N and Sugamura K: Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol. 72:3018–3028. 1998. View Article : Google Scholar : PubMed/NCBI
21	Hsu TC, Wu WJ, Chen MC and Tsay GJ: Human parvovirus B19 non-structural protein (NS1) induces apoptosis through mitochondria cell death pathway in COS-7 cells. Scand J Infect Dis. 36:570–577. 2004. View Article : Google Scholar : PubMed/NCBI
22	Poole BD, Kivovich V, Gilbert L and Naides SJ: Parvovirus B19 nonstructural protein-induced damage of cellular DNA and resultant apoptosis. Int J Med Sci. 8:88–96. 2011. View Article : Google Scholar : PubMed/NCBI
23	Fu Y, Ishii KK, Munakata Y, Saitoh T, Kaku M and Sasaki T: Regulation of Tumor necrosis factor alpha promoter by human parvovirus B19 NS1 through activation of AP-1 and AP-2. J Virol. 76:5395–5403. 2002. View Article : Google Scholar : PubMed/NCBI
24	Cascão R, Fonseca JE and Moita LF: Celastrol: A spectrum of treatment opportunities in chronic diseases. Front Med (Lausanne). 4:692017. View Article : Google Scholar : PubMed/NCBI
25	Kun-Ming C, Chih-Hsien C, Chen-Fang L, Ting-Jung W, Hong-Shiue C and Wei-Chen L: Potential anticancer effect of celastrol on hepatocellular carcinoma by suppressing CXCR4-related signal and impeding tumor growth in vivo. Arch Med Res. 51:297–302. 2020. View Article : Google Scholar : PubMed/NCBI
26	Cui Y, Jiang X and Feng J: The therapeutic potential of triptolide and celastrol in neurological diseases. Front Pharmacol. 13:10249552022. View Article : Google Scholar : PubMed/NCBI
27	Li Z, Zhang J, Duan X, Zhao G and Zhang M: Celastrol: A promising agent fighting against cardiovascular diseases. Antioxidants (Basel). 11:15972022. View Article : Google Scholar : PubMed/NCBI
28	Tseng CK, Hsu SP, Lin CK, Wu YH, Lee JC and Young KC: Celastrol inhibits hepatitis C virus replication by upregulating heme oxygenase-1 via the JNK MAPK/Nrf2 pathway in human hepatoma cells. Antiviral Res. 146:191–200. 2017. View Article : Google Scholar : PubMed/NCBI
29	Chen DY, Chen YM, Chen HH, Hsieh CW, Gung NR, Hung WT, Tzang BS and Hsu TC: Human parvovirus B19 nonstructural protein NS1 activates NLRP3 inflammasome signaling in adult-onset Still's disease. Mol Med Rep. 17:3364–3371. 2018.PubMed/NCBI
30	Wu J, Chen X, Ye H, Yao M, Li S and Chen L: Nonstructural protein (NS1) of human parvovirus B19 stimulates host innate immunity and blunts the exogenous type I interferon signaling in vitro. Virus Res. 222:48–52. 2016. View Article : Google Scholar : PubMed/NCBI
31	Takasawa N, Munakata Y, Ishii KK, Takahashi Y, Takahashi M, Fu Y, Ishii T, Fujii H, Saito T, Takano H, et al: Human parvovirus B19 transgenic mice become susceptible to polyarthritis. J Immunol. 173:4675–4683. 2004. View Article : Google Scholar : PubMed/NCBI
32	Chisaka H, Morita E, Murata K, Ishii N, Yaegashi N, Okamura K and Sugamura K: A transgenic mouse model for non-immune hydrops fetalis induced by the NS1 gene of human parvovirus B19. J Gen Virol. 83((Pt 2)): 273–281. 2002. View Article : Google Scholar : PubMed/NCBI
33	Bachelier K, Biehl S, Schwarz V, Kindermann I, Kandolf R, Sauter M, Ukena C, Yilmaz A, Sliwa K, Bock CT, et al: Parvovirus B19-induced vascular damage in the heart is associated with elevated circulating endothelial microparticles. PLoS One. 12:e01763112017. View Article : Google Scholar : PubMed/NCBI
34	Chen DY, Chen YM, Tzang BS, Lan JL and Hsu TC: Th17-related cytokines in systemic lupus erythematosus patients with dilated cardiomyopathies: A possible linkage to parvovirus B19 infection. PLoS One. 9:e1138892014. View Article : Google Scholar : PubMed/NCBI
35	Nam NH: Naturally occurring NF-kappaB inhibitors. Mini Rev Med Chem. 6:945–951. 2006. View Article : Google Scholar : PubMed/NCBI
36	Dirsch VM, Kiemer AK, Wagner H and Vollmar AM: The triterpenoid quinonemethide pristimerin inhibits induction of inducible nitric oxide synthase in murine macrophages. Eur J Pharmacol. 336:211–217. 1997. View Article : Google Scholar : PubMed/NCBI
37	Jin HZ, Hwang BY, Kim HS, Lee JH, Kim YH and Lee JJ: Antiinflammatory constituents of Celastrus orbiculatus inhibit the NF-kappaB activation and NO production. J Nat Prod. 65:89–91. 2002. View Article : Google Scholar : PubMed/NCBI
38	Kim Y, Kang H, Jang SW and Ko J: Celastrol inhibits breast cancer cell invasion via suppression of NF-ĸB-mediated matrix metalloproteinase-9 expression. Cell Physiol Biochem. 28:175–184. 2011. View Article : Google Scholar : PubMed/NCBI
39	Venkatesha SH, Dudics S, Astry B and Moudgil KD: Control of autoimmune inflammation by celastrol, a natural triterpenoid. Pathog Dis. 74:ftw0592016. View Article : Google Scholar : PubMed/NCBI
40	Zhou D, Li X, Xiao X, Wang G, Chen B, Song Y, Liu X, He Q, Zhang H, Wu Q, et al: Celastrol targets the ChREBP-TXNIP axis to ameliorates type 2 diabetes mellitus. Phytomedicine. 110:1546342023. View Article : Google Scholar : PubMed/NCBI
41	Cascão R, Vidal B, Carvalho T, Lopes IP, Romão VC, Goncalves J, Moita LF and Fonseca JE: Celastrol efficacy by oral administration in the adjuvant-induced arthritis model. Front Med. (Lausanne). 7:4552020.
42	Gao Q, Qin H, Zhu L, Li D and Hao X: Celastrol attenuates collagen-induced arthritis via inhibiting oxidative stress in rats. Int Immunopharmacol. 84:1065272020. View Article : Google Scholar : PubMed/NCBI